HARTMANN GROUP’s Post

Measles isn’t just a disease of the past; it’s still one of the most contagious viruses today. Why does it spread so easily, and why is protection so important? 👉 Swipe through this month’s Pathogen Profile to find out.

HARTMANN delivers a competent, disciplined quarter, but not a transformative one. The company is stabilizing and improving profitability, yet the growth profile remains modest, and structural European headwinds limit upside. For an investor or strategic analyst, Q1 2026 confirms: Low risk of deterioration, Moderate probability of steady improvement, Low probability of breakout growth without portfolio action (e.g., Kneipp) or regulatory relief.

Like
Reply

Anne Riff ! Bravo ! J'espère que tout bien va bien ! N'hésites à contacter ! Éric Robert 😀 😄 😆 😀 😄

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories